StockData
Rigel Pharmaceuticals Inc logo

Rigel Pharmaceuticals Inc (RIGL) stock

RIGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/30
$42.53−0.39 (-0.91%)

Close on Nov 18, 2026Market cap $794.46MP/E 2.7Yield –

Rigel Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Rigel Pharmaceuticals's free cash flow for the twelve months ending Dec 31, 2022 was -$74.21M, down 1513.2% year over year. For fiscal 2022 it was -$74.21M, down 1513.2% from the year before. The highest annual figure on record is $43.18M in fiscal 2010.

Annual free cash flow

PeriodPeriod endValueChange
FY2022Dec 31, 2022-$74.21M-1513.2%
FY2021Dec 31, 2021$5.25M–
FY2020Dec 31, 2020-$53.45M–
FY2019Dec 31, 2019-$42.97M–
FY2018Dec 31, 2018-$59.93M–
FY2017Dec 31, 2017-$77.72M–
FY2016Dec 31, 2016-$76.69M–
FY2015Dec 31, 2015-$23.96M–
FY2014Dec 31, 2014-$70.17M–
FY2013Dec 31, 2013-$87.30M–
FY2012Dec 31, 2012-$88.59M–
FY2011Dec 31, 2011-$71.68M-266.0%
FY2010Dec 31, 2010$43.18M–
FY2009Dec 31, 2009-$102.92M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2022Dec 31, 2022-$21.98M–
Q3 FY2022Sep 30, 2022-$13.49M–
Q2 FY2022Jun 30, 2022-$12.88M-123.5%
Q1 FY2022Mar 31, 2022-$25.86M–
Q4 FY2021Dec 31, 2021-$19.07M–
Q3 FY2021Sep 30, 2021-$10.47M–
Q2 FY2021Jun 30, 2021$54.81M–
Q1 FY2021Mar 31, 2021-$20.03M–
Q4 FY2020Dec 31, 2020-$16.08M–
Q3 FY2020Sep 30, 2020-$19.68M–
Q2 FY2020Jun 30, 2020-$13.99M–
Q1 FY2020Mar 31, 2020-$3.70M–
Q4 FY2019Dec 31, 2019-$10.26M-188.6%
Q3 FY2019Sep 30, 2019-$14.99M–
Q2 FY2019Jun 30, 2019-$16.77M–
Q1 FY2019Mar 31, 2019-$946.00K–
Q4 FY2018Dec 31, 2018$11.58M–
Q3 FY2018Sep 30, 2018-$20.24M–
Q2 FY2018Jun 30, 2018-$27.68M–
Q1 FY2018Mar 31, 2018-$23.59M–
Q4 FY2017Dec 31, 2017-$19.77M–
Q3 FY2017Sep 30, 2017-$17.67M–
Q2 FY2017Jun 30, 2017-$19.48M–
Q1 FY2017Mar 31, 2017-$20.80M–
Q4 FY2016Dec 31, 2016-$12.47M–
Q3 FY2016Sep 30, 2016-$22.82M–

More Rigel Pharmaceuticals figures

See a number that looks wrong?